EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1

Bong-Kyu Kim iD, Jaehong Min iD, Sang-Hee Park iD, Subeen Shin iD, Sangbin Yu iD, Jeong-Eun Park iD, Sujin Kim iD, Wooju Park iD, Jihoon Ko iD, Sunjong Kwon iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.71568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Bong-Kyu Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, EyeGene Inc., Uiwang-si, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Vascular Endothelial Growth Factor A, Receptors, Vascular Endothelial Growth Factor, Angiogenesis. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korean ARPA-H.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current anti‐VEGF monotherapies for neovascular age‐related macular degeneration (AMD) and diabetic retinopathy (DR) are limited by incomplete therapeutic responses, drug resistance, and the high burden of frequent intravitreal injections (IVTs). Although extensive research is underway to improve therapeutic outcomes, there remains a critical need for more effective strategies. To address this limitation, a bicistronic rAAV8 vector, Afb/cAng1, was developed to co‐express aflibercept (Afb) and COMP‐Ang1 (cAng1), simultaneously inhibiting VEGF signaling and activating the Tie2 pathway. In vitro characterization using conditioned medium containing secreted Afb/cAng1 showed that the treatment effectively suppresses VEGF‐induced VEGFR2 phosphorylation to below basal levels while robustly activating Tie2. Consequently, the conditioned medium significantly inhibited endothelial cell migration and tube formation, and restored VE‐cadherin expression compromised by VEGF stimulation or hyperglycemic conditions. Afb/cAng1 in a 3D angiogenesis‐on‐a‐chip model reduces neovascular area and vascular permeability, showing superior efficacy compared to Afb (Eylea). In vivo choroidal neovascularization (CNV) analysis confirmed dose‐dependent anti‐angiogenic efficacy of rAAV8‐Afb/cAng1, comparable to that of Eylea. These findings highlight Afb/cAng1 as a dual‐targeting gene therapy strategy that concurrently suppresses pathological angiogenesis and promotes vascular stabilization through coordinated VEGF inhibition and Tie2 activation in AMD and DR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorAngiogenesisHumansAnimalsCell MovementCadherin 5CadherinsReceptor, TIE-2Human Umbilical Vein Endothelial CellsCapillary PermeabilityVascular Endothelial Growth Factor Receptor-2DependovirusMiceAntigens, CD

Stichwörter der Autor:innen

adeno‐associated virusafliberceptage‐related macular degenerationangiogenesischoroidal neovascularizationcomp‐Ang1

Substanzen

afliberceptRecombinant Fusion ProteinsVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorCOMP-Ang1 fusion proteinCadherin 5CadherinsReceptor, TIE-2Vascular Endothelial Growth Factor Receptor-2Antigens, CD

Autor:innen und Institutionen

  • R&D Center, EyeGene Inc., Uiwang-si, Gyeonggi-do, Republic of Korea.
  • Department of BioNano Technology, Gachon University, Seongnam-si, Gyeonggi-do, Republic of Korea.
  • Department of Bioengineering, Hanyang University, Seoul, Republic of Korea.

ORCID-Profile: Bong-Kyu Kim, Jaehong Min, Sang-Hee Park, Subeen Shin, Sangbin Yu, Jeong-Eun Park, Sujin Kim, Wooju Park, Jihoon Ko, Sunjong Kwon

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korean ARPA-H
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Kim, B. K., Min, J., Park, S. H., Shin, S., Yu, S., Park, J. E., Kim, S., Park, W., Ko, J., & Kwon, S. (2026). Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71568

Vancouver

Kim BK, Min J, Park SH, Shin S, Yu S, Park JE, et al. Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71568

BibTeX
@article{Kim2026,
  author = {Kim, Bong-Kyu and Min, Jaehong and Park, Sang-Hee and Shin, Subeen and Yu, Sangbin and Park, Jeong-Eun and Kim, Sujin and Park, Wooju and Ko, Jihoon and Kwon, Sunjong},
  title = {Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71568}
}
Kostenlos starten →